Peptides

Semaglutide (Ozempic/Wegovy) Research Overview

Research overview of semaglutide, the GLP-1 receptor agonist behind Ozempic and Wegovy. Clinical trial data, mechanism of action, and Australian research context.

Semaglutide (Ozempic/Wegovy) Research Overview

Semaglutide is a research compound belonging to the glucagon-like peptide-1 receptor agonist (GLP-1 RA) class. Originally developed for type 2 diabetes research, semaglutide has become one of the most extensively studied incretin-based compounds in clinical trials worldwide. It is marketed under the brand names Ozempic (injectable, for type 2 diabetes) and Wegovy (injectable, for chronic weight management), with an oral formulation also available as Rybelsus.

Mechanism of Action

Semaglutide is a synthetic analogue of native human GLP-1, a gut-derived incretin hormone. Researchers have observed that semaglutide binds to the GLP-1 receptor, stimulating insulin secretion in a glucose-dependent manner while suppressing glucagon release. This dual action helps regulate blood glucose levels with a reduced risk of hypoglycaemia compared to earlier insulin secretagogues.

What distinguishes semaglutide from earlier GLP-1 RAs is its structural modification — a fatty diacid chain attached to position 26 of the peptide backbone via a linker. This modification enables strong, non-covalent binding to serum albumin, giving semaglutide an extended circulating half-life of approximately one week (168 hours). The compound also incorporates two amino acid substitutions (Aib at position 8) that confer resistance to dipeptidyl peptidase-4 (DPP-4) enzymatic degradation, further extending its biological activity.

These pharmacokinetic properties allow once-weekly subcutaneous dosing, a significant improvement over earlier GLP-1 RAs like exenatide (twice daily) and liraglutide (daily).

Clinical Trial Programme

SUSTAIN Programme (Type 2 Diabetes)

The SUSTAIN (Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes) programme encompassed a series of Phase 3 trials evaluating semaglutide in adults with type 2 diabetes:

  • SUSTAIN 1 (monotherapy): Researchers observed HbA1c reductions of 1.5% (0.5 mg) to 1.8% (1.0 mg) versus 0.1% with placebo at 30 weeks.
  • SUSTAIN 2: Compared to sitagliptin 100 mg, semaglutide 1.0 mg achieved superior HbA1c reduction (1.6% vs 0.5%) at 56 weeks.
  • SUSTAIN 6: This cardiovascular outcomes trial (n=3,297) demonstrated a 26% relative risk reduction in major adverse cardiovascular events (MACE) with semaglutide versus placebo (HR 0.74, 95% CI 0.58–0.95). This was a landmark finding for the GLP-1 RA class.
  • SUSTAIN 7: Head-to-head against dulaglutide, semaglutide showed statistically superior HbA1c reductions and weight loss at both dose comparisons.

PIONEER Programme (Oral Semaglutide)

The PIONEER trials evaluated the oral formulation of semaglutide, which uses sodium N-(8-[2-hydroxybenzoyl]amino) caprylate (SNAC) as an absorption enhancer:

  • PIONEER 1: Oral semaglutide 14 mg achieved HbA1c reductions of 1.0% versus 0.3% with placebo at 26 weeks.
  • PIONEER 4: Compared to liraglutide 1.8 mg, oral semaglutide 14 mg showed non-inferior HbA1c reduction and superior weight loss.
  • PIONEER 6: The cardiovascular safety trial (n=3,183) showed no increased cardiovascular risk, with a numerical trend toward MACE reduction (HR 0.79, 95% CI 0.57–1.11).

STEP Programme (Weight Management)

The STEP (Semaglutide Treatment Effect in People with Obesity) trials evaluated semaglutide 2.4 mg weekly for weight management:

  • STEP 1: Researchers observed mean body weight reductions of 14.9% with semaglutide versus 2.4% with placebo at 68 weeks. Over 86% of participants achieved ≥5% weight loss.
  • STEP 2: In adults with type 2 diabetes, semaglutide 2.4 mg achieved 9.6% weight reduction versus 3.4% with placebo.
  • STEP 3: Combined with intensive behavioural therapy, semaglutide achieved 16.0% weight reduction.
  • STEP 5: Demonstrated sustained weight loss over 104 weeks (two years), with participants maintaining approximately 15.2% weight reduction.

Oral vs Injectable Formulations

Semaglutide is available in both injectable and oral formulations, though with important distinctions:

  • Injectable (subcutaneous): Available as Ozempic (up to 2.0 mg weekly for diabetes) and Wegovy (2.4 mg weekly for weight management). The injectable route provides higher and more consistent bioavailability.
  • Oral: Available as Rybelsus (up to 14 mg daily for diabetes). The oral formulation requires fasting administration with a small amount of water, followed by a 30-minute wait before eating. Bioavailability is lower and more variable than the injectable route.

Ongoing research is investigating higher-dose oral semaglutide formulations (25 mg and 50 mg) that may bridge the efficacy gap between oral and injectable administration.

Regulatory Status in Australia

In Australia, semaglutide-containing products are classified as Schedule 4 (Prescription Only) compounds:

  • Ozempic (semaglutide injection) is approved by the Therapeutic Goods Administration (TGA) for glycaemic control in adults with type 2 diabetes. It is listed on the Pharmaceutical Benefits Scheme (PBS) for eligible patients with type 2 diabetes.
  • Wegovy (semaglutide 2.4 mg injection) was approved by the TGA for chronic weight management and has been listed on the PBS under specific criteria for adults with obesity.
  • Rybelsus (oral semaglutide) is TGA-approved for type 2 diabetes.

Supply constraints have periodically affected availability of semaglutide products in Australia, reflecting global demand patterns.

Research Context and Ongoing Studies

Semaglutide continues to be investigated across multiple therapeutic areas beyond diabetes and obesity:

  • SELECT Trial: A cardiovascular outcomes trial in adults with overweight/obesity and established cardiovascular disease (without diabetes), which reported a 20% reduction in MACE events.
  • EVOKE and EVOKE+: Trials investigating semaglutide in early Alzheimer’s disease, based on preclinical evidence of GLP-1 receptor-mediated neuroprotective effects.
  • OASIS: Trials evaluating semaglutide 50 mg oral formulation for weight management.
  • STEP-HFpEF: Investigating semaglutide in heart failure with preserved ejection fraction in people with obesity.

The compound remains central to the growing field of incretin-based research, which has expanded to include dual and triple agonist approaches.

Researchers studying semaglutide may also be interested in:

Disclaimer: This page is for research and educational purposes only. No therapeutic claims are made. Semaglutide is a Schedule 4 (Prescription Only) compound in Australia. This information does not constitute medical advice. Consult a qualified healthcare professional for any health-related decisions. All data referenced is drawn from published peer-reviewed clinical trials.